secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059498
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio appoints Dr. Kemi Olugemo as Chief Medical Officer
------------------------------------------------------------

- Dr. Olugemo joined as CMO effective May 13, 2024; prior role was VP of Global Clinical Development at Ultragenyx.
- Previously Head of Clinical Development at Laronde (now Sail Bio) and Executive Director at Ionis Pharmaceuticals.
- Over 10 years of neurology and rare disease clinical development experience, including global approvals.
- M.D. from University of Maryland School of Medicine with fellowship in Neuroimmunology & Multiple Sclerosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024059498/0000950170-24-059498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024059498/krro-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer